Latest news with #AdemiFirm
Business Wire
5 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Verve will receive $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. Verve insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Verve by imposing a significant penalty if Verve accepts a competing bid. We are investigating the conduct of the Verve board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
6 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Cantaloupe, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Cantaloupe (NASDAQ: CTLP) for possible breaches of fiduciary duty and other violations of law in its transaction with 365 Retail Markets. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the cash transaction, shareholders of Cantaloupe will receive $11.20 per share, with an equity value of approximately $848 million. Cantaloupe insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Cantaloupe by imposing a significant penalty if Cantaloupe accepts a competing bid. We are investigating the conduct of the Cantaloupe board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
6 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether FineMark Holdings, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating FineMark (OTCQX: FNBT) for possible breaches of fiduciary duty and other violations of law in its transaction with Commerce Bancshares. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of FineMark will receive a fixed exchange ratio of 0.690 shares of Commerce common stock for each share of FineMark common stock. The per share value equates to $41.87 for FineMark shareholders based on the closing price of Commerce common stock on June 13, 2025, or approximately $585 million in the aggregate including the conversion of outstanding preferred stock. FineMark insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for FineMark by imposing a significant penalty if FineMark accepts a competing bid. We are investigating the conduct of the FineMark board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
6 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Sage will receive $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. Sage insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Sage by imposing a significant penalty if Sage accepts a competing bid. We are investigating the conduct of the Sage board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
04-06-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Flowserve Corporation Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Flowserve (NYSE: FLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Chart Industries. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, shareholders of Flowserve shareholders will own approximately 46.5% of the combined company. Flowserve insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Flowserve by imposing a significant penalty if Flowserve accepts a competing bid. We are investigating the conduct of the Flowserve board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
